00:35 , Oct 21, 2017 |  BioCentury  |  Product Development

Naked ambition

Proof-of-concept data from miRagen Therapeutics Inc. show systemic delivery of its lead candidate can shrink lesions in cutaneous T cell lymphoma, and that its oligonucleotide platform can achieve broad distribution and a long half-life without...
21:05 , Jul 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Muscular atrophy Studies in cell culture and mice suggest inhibiting miR-29b could help treat muscular atrophy. In a mouse skeletal myoblast cell line-based model of chemical-induced muscle cell atrophy, an miR-29b inhibitor tool compound increased...
23:21 , Nov 3, 2016 |  BC Week In Review  |  Company News

Signal, miRagen deal

miRagen will merge with Signal to form a publicly traded microRNA company focused on hematological malignancies, pathological fibrosis and cardiovascular and neurodegenerative diseases. The surviving entity will retain miRagen's name and trade on NASDAQ. The...
23:20 , Nov 1, 2016 |  BC Extra  |  Company News

miRagen finds public path via Signal merger

miRagen Therapeutics Inc. (Boulder, Colo.) will merge with Signal Genetics Inc. (NASDAQ:SGNL) to form a publicly traded microRNA company focused on hematological malignancies, pathological fibrosis and cardiovascular and neurodegenerative diseases. The surviving entity will retain...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

MiR-29: Phase I started

miRagen began a double-blind, placebo-controlled, Canadian Phase I trial of MRG-201 in about 80 healthy volunteers and patients. In the first part, volunteers will receive single and multiple ascending doses of intradermal MRG-201. In the...
02:25 , Nov 11, 2015 |  BC Extra  |  Financial News

miRagen raises $41 series C

MicroRNA company miRagen Therapeutics Inc. raised $41 million in a series C round co-led by MRL Ventures and JAFCO. Other new investors Brace Pharma Capital and MP Healthcare Venture Management joined existing investors Atlas Venture,...
08:00 , Feb 16, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Aneurysm MicroRNA-29b (miR-29b) Studies in mice suggest inhibiting miR-29b could help...
08:00 , Nov 19, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute myeloid leukemia (AML) ...